Biotech RadarJobs updated

COMPANY

Eisai Inc.

HQ: Nutley, NJ (US office) source · us.eisai.com ↗

FDA-approved therapeutic company FDA-cleared device company

Also known as Eisai Pharmaceutical · 5 sources

Keywords: neurology oncology

Location: Nutley, NJ (US office) · source · Oct 15, 2026

Profile checked Oct 10, 2026

4FDA records (2 yrs)

Timeline

  1. FDA FDA New indication / efficacy supplement: LENVIMA (lenvatinib mesylate) — NDA206947/35, Sep 24, 2026. Applicant at approval: Eisai Inc. source ↗
  2. Partnership Partnership / licensing announced Sep 14, 2026. Source: company's own press page. source ↗
  3. FDA FDA New indication / efficacy supplement: LEQEMBI IQLIK (lecanemab-irmb) — BLA761375/1, Jul 13, 2026. Applicant at approval: Eisai Inc. source ↗
  4. Raise Private placement: amount not published, announced Jun 15, 2026. Source: company's own press page. source ↗
  5. FDA FDA New indication / efficacy supplement: LENVIMA (lenvatinib mesylate) — NDA206947/33, Jan 29, 2025. Applicant at approval: Eisai Inc. source ↗
  6. FDA FDA New indication / efficacy supplement: LEQEMBI (lecanemab-irmb) — BLA761269/5, Jan 24, 2025. Applicant at approval: Eisai Inc. source ↗

Funding

Raised: amount not published. Last 2 years.

FDA records (last 2 years)

Connect

See your connections at Eisai on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-12

Feedback